Please login to the form below

ASP015K

This page shows the latest ASP015K news and features for those working in and with pharma, biotech and healthcare.

Deal Watch table for December 2014

Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3).
Pharma deals during October 2012

Heading the deal table is the $945m licence between Astellas Pharma and Janssen for the exclusive rights outside Japan to ASP015K, an oral janus kinase (JAK) inhibitor that is undergoing phase ... Astellas / Janssen. Licence. ASP015K for RA, psoriasis

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Commercial Finance Director, Healthcare Marketing Communications...: up to £90K

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Add my company

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Mistrust in medical research: a patient perspective: The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease: Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients: We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...